Netcall’s (NET) “Buy” Rating Reiterated at Canaccord Genuity Group

Netcall (LON:NET)‘s stock had its “buy” rating reiterated by research analysts at Canaccord Genuity Group in a research report issued on Wednesday,Digital Look reports. They currently have a GBX 160 target price on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 56.86% from the company’s current price.

Separately, Berenberg Bank reiterated a “buy” rating and set a GBX 165 price objective on shares of Netcall in a report on Wednesday. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Netcall currently has a consensus rating of “Buy” and a consensus target price of GBX 162.50.

Netcall Stock Down 1.0%

Shares of Netcall stock traded down GBX 1 on Wednesday, reaching GBX 102. The stock had a trading volume of 393,725 shares, compared to its average volume of 387,212. The company has a quick ratio of 0.88, a current ratio of 0.86 and a debt-to-equity ratio of 2.37. The stock has a market capitalization of £173.89 million, a P/E ratio of 42.32 and a beta of 0.23. The company has a 50 day moving average price of GBX 119.01 and a 200 day moving average price of GBX 117.98. Netcall has a 1 year low of GBX 88 and a 1 year high of GBX 138.

Netcall (LON:NET) last posted its earnings results on Wednesday, March 4th. The company reported GBX 2.43 EPS for the quarter. Netcall had a net margin of 8.44% and a return on equity of 9.39%. As a group, equities research analysts forecast that Netcall will post 3.7029017 EPS for the current year.

Netcall Company Profile

Netcall is a UK-based enterprise software company that unites automation and customer engagement in one AI-powered platform. Its Liberty platform makes work easier by digitising processes and simplifying customer interactions in a single, easy-to-use solution that reduces complexity. Today, around 600 organisations across healthcare, government and financial services rely on Netcall for mission‑critical workflows, including two‑thirds of NHS Acute Health Trusts and major enterprises such as Legal & General, Baloise and Santander.